Immunocore Holdings plc (IMCR) Stock Price & Analysis
Immunocore Holdings plc (IMCR) closed at USD 32.12 on Thursday, October 22, 2026, up 0.09% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 32.09; the Oct 22, 2026 session ranged USD 31.3–32.76 on volume of 283,250 shares. Market capitalization is $1.65B, with a 52-week range of USD 27.5–40.72 (NMS). Source: Nexqual, retrieved October 23, 2026 at 10:12 UTC.
Also available as compact Markdown for AI agents: nexqual.com/IMCR.md
Key facts (IMCR)
- Last four reported quarters (through Jun 30, 2026): revenue $431M, net income -$18.1M (-4.2% margin), free cash flow -$41.2M (SEC filings).
- Analysts: Buy (mean 2.15 on a 1–5 scale) (13 analysts), mean target USD 62.73 (range 34–100).
- Total return with dividends: 1Y +1.6% vs S&P 500 +14.9%; 5Y -15.1% vs S&P 500 +80.3%.
- Next earnings: 2026-11-05, EPS estimate USD -0.13, revenue estimate $113M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (IMCR)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $36.5M | $174M | $249M | $310M | $400M | $431M |
| Gross profit | $36.5M | $173M | $248M | $307M | $395M | — |
| Operating income | -$175M | -$51.7M | -$59.6M | -$70.5M | -$45.4M | -$22.6M |
| Net income | -$180M | -$52.5M | -$55.3M | -$51.1M | -$35.5M | -$18.1M |
| EPS (diluted) | -$4.24 | -$1.15 | -$1.13 | -$1.02 | -$0.71 | — |
| Free cash flow | -$144M | -$51.4M | -$2.5M | $20.9M | -$15.1M | -$41.2M |
| Gross margin | 100.0% | 99.4% | 99.6% | 99.1% | 98.7% | — |
| Operating margin | -478.5% | -29.7% | -23.9% | -22.7% | -11.3% | -5.2% |
| Net margin | -493.4% | -30.1% | -22.2% | -16.5% | -8.9% | -4.2% |
| Revenue growth | — | +377.9% | +43.1% | +24.4% | +29.0% | — |
| Cash + short-term investments | $321M | $402M | $443M | $820M | $864M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (IMCR)
P/S 3.8x · P/B 3.9x · FCF yield -2.49% · Earnings yield -1.09%
Analysts (IMCR)
Consensus Buy (mean 2.15 on a 1–5 scale), 13 analysts; mean target USD 62.73 (low 34, high 100).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-03 | Mizuho | Target raised | Neutral | $34 → $35 |
Total return (dividends reinvested) (IMCR)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +1.6% | -15.1% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +1.6% | -3.2% |
| Volatility (annualized) | 36.8% | 46.8% |
| Max drawdown | -30.9% (Dec 2025→Jun 2026) | -64.4% (Feb 2024→Apr 2025) |
IMCR analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.13 | $0.00 | -4448.3% | $113.3M | 12 |
| Next quarter (ends Dec 2026) | $-0.18 | $-0.14 | +24.6% | $116.5M | 12 |
| Current fiscal year (ends Dec 2026) | $-0.04 | $0.14 | -129.0% | $452.3M | 11 |
| Next fiscal year (ends Dec 2027) | $-0.77 | $-0.52 | +48.1% | $489.0M | 12 |
Key Statistics (as of October 23, 2026 at 10:12 UTC)
| Price | USD 32.12 |
|---|---|
| Change | ▲ 0.09% (up) |
| Previous Close | USD 32.09 |
| Open | USD 32.04 |
| Day Range | USD 31.3 – 32.76 |
| 52-Week Range | USD 27.5 – 40.72 |
| Volume | 283,250 shares |
| Market Cap | $1.65B |
| Exchange | NMS |
Technical Analysis (IMCR)
Nexqual's technical model rates IMCR "NEUTRAL" based on 3 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 10:12 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 53.86 (neutral) |
| vs SMA50 | Below (USD 32.85) |
| MACD | -0.32 (negative) |
Analyst Ratings (IMCR)
Wall Street analysts rate IMCR "Buy" based on 13 analysts, with a mean price target of USD 62.73 (range USD 34–100), per Nexqual as of October 23, 2026 at 10:12 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 13 |
| Mean Target | USD 62.73 |
| High Target | USD 100 |
| Low Target | USD 34 |
| Buy / Hold / Sell | 9 / 4 / 0 |
Earnings (IMCR)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.13 |
| Revenue Estimate | $113.35M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.02 vs est 0.02 ▼ miss |
| 2026-03-31 | USD 0.25 vs est -0.26 ▲ beat |
| 2025-12-31 | USD -0.6 vs est -0.2 ▼ miss |
| 2025-09-30 | USD 0 vs est -0.24 ▲ beat |
Source: Nexqual, October 23, 2026 at 10:12 UTC.
Financials & Fundamentals (IMCR)
| Total Revenue | $430.78M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +18.30% |
| Gross Margin | +32.87% |
| Operating Margin | -2.58% |
| Profit Margin | -4.20% |
| ROE | -4.47% |
| Debt / Equity | 1.04 |
| Current Ratio | 4.47 |
| Total Cash | $880.21M |
| Total Debt | $434.96M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | -$41.15M (-9.6% of revenue) |
Source: Nexqual, October 23, 2026 at 10:12 UTC.
Financial Health Score (IMCR)
Nexqual rates Immunocore Holdings plc's overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 10:12 UTC.
| Growth | Strong — Revenue +29% YoY (annual) |
|---|---|
| Profitability | Weak — Gross margin 33%, operating -3% (last 12 months) |
| Balance Sheet | Mixed — $880M cash vs $435M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$41M (last 4 quarters to Jun 2026, SEC), burning cash |
| Efficiency | Critical — ROE -4%, ROA -0.2% |
Ownership (IMCR)
| Insider Ownership | +0.07% |
|---|---|
| Institutional Ownership | +103.20% |
| Shares Outstanding | 51.50M |
| Float | 45.83M |
| Short % of Float | +17.05% |
Source: Nexqual, October 23, 2026 at 10:12 UTC.
Leadership (IMCR)
Immunocore Holdings plc is led by Bahija Jallal, CEO & Executive Director, per Nexqual as of October 23, 2026 at 10:12 UTC.
| CEO & Executive Director | Bahija Jallal |
|---|---|
| CFO, Executive VP & Head of Corporate Development | Travis Alan Coy |
| Executive VP & Chief Operating Officer | Kripa Ram |
| Vice President of Investor Relations | Ryan Baker |
| Vice President of Communications | Sébastien Desprez |
Major Backers & Investors (IMCR)
Notable institutional backers of Immunocore Holdings plc include Wellington Management, RTW Investments LP, FMR, LLC, according to Nexqual as of October 23, 2026 at 10:12 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Wellington Management | 11.11% |
| RTW Investments LP | 9.46% |
| FMR, LLC | 8.36% |
| Primecap Management Company | 7.06% |
| Bellevue Group AG | 5.41% |
| Tang Capital Management, LLC | 5.14% |
| Vestal Point Capital, LP | 3.5% |
| Two Sigma Investments, LP | 3.2% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 12.79% |
Source: Nexqual, October 23, 2026 at 10:12 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 307.82 | ▼ 2.21% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 90.9 | ▲ 2.57% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.14 | ▼ 3.28% |
| PRAX | Praxis Precision Medicines, Inc | USD 258.92 | ▲ 0.96% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 43.91 | ▼ 0.81% |
| ABVX | Abivax SA | USD 90.23 | ▼ 3.49% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:12 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt